nach oben

BioDrugs

Erschienen in:

01.09.2005 | Therapy Review

The Role of Radioimmunotherapy with Yttrium- 90 Ibritumomab Tiuxetan in the Treatment of Non-Hodgkin Lymphoma

verfasst von: Dr Bruce D. Cheson

Erschienen in: BioDrugs | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

Radioimmunotherapy (RIT) is among the newest modalities for treating the diverse neoplasms known as non-Hodgkin lymphomas (NHLs). The first RIT agent approved by the US FDA was yttrium-90 (⁹⁰Y) ibritumomab tiuxetan in February 2002. This radioimmunoconjugate consists of the monoclonal IgG1 antibody ibritumomab (the murine parent of rituximab) bound to the chelator tiuxetan and linked by a stable thiourea covalent bond to the β-emitting radionuclide ⁹⁰Y. RIT with ⁹⁰Y ibritumomab tiuxetan is completed in 7–9 days on an outpatient basis, with only minimal (universal) precautions required. The dosing of ⁹⁰Y ibritumomab tiuxetan is based on patient weight and platelet count, after normal biodistribution with indium-111 ibritumomab tiuxetan has been confirmed. Treatment with ⁹⁰Y ibritumomab tiuxetan has produced high response rates and long-term benefits in patients with relapsed or refractory follicular and low-grade NHL, including those in whom rituximab therapy has failed. Its toxicity is primarily hematologic, with the hematologic nadirs generally occurring at 7–9 weeks after treatment. Severe infections are uncommon, with infrequent need for supportive measures such as administration of growth factors and transfusions of blood components. There is little nonhematologic toxicity with RIT and it is generally related to infusion-associated reactions. Clinical trials are investigating ways of increasing the efficacy of RIT. In particular, using RIT earlier in the course of treatment of NHL appears to be a promising approach and has been shown to produce better results than when it is used later. Ongoing research is needed to maximize the efficacy of RIT and minimize adverse events, with the goal of developing a multimodality approach that combines RIT with other biologic agents and possibly chemotherapy as frontline treatment to improve the outcomes in patients with NHL.

Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10–30PubMedCrossRef

Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17(12): 3835–49PubMed

Armitage JO, Weisenberger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–95PubMed

Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 1993; 20(5 Suppl. 5): 75–88PubMed

Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14(4): 1282–90

Gospodarowicz MK, Bush RS, Brown TC, et al. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1984; 10: 489–97PubMedCrossRef

Vose JM. Classification and clinical course of low-grade non-Hodgkin’s lymphomas with an overview of therapy. Ann Oncol 1996; 7Suppl. 6: S13–19PubMedCrossRef

Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–27PubMedCrossRef

Brandt L, Kimby E, Nygren P, et al. A systematic overview of chemotherapy effects in indolent non-Hodgkin’s lymphoma. Acta Oncol 2001; 40: 213–23PubMedCrossRef

10.

McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–33PubMed

11.

Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–32PubMed

12.

Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–6PubMedCrossRef

13.

Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005; 23: 1103–8PubMedCrossRef

14.

Hochster HS, Weller E, Ryan T, et al. Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) [abstract 6502]. Proc Am Soc Clin Oncol Meeting 2004; 23: 556

15.

Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004; 103: 4416–23PubMedCrossRef

16.

Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20: 4261–7PubMedCrossRef

17.

Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135–43PubMed

18.

Hainsworth JD. Prolonging remission with rituximab maintenance therapy. Semin Oncol 2004; 31(1 Suppl. 2): 17–21PubMedCrossRef

19.

Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma. A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088–95PubMedCrossRef

20.

Marcus R, Imrie K, Belch A, et al. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin’s lymphoma [abstract 87]. Blood 2003; 102Suppl. 1: 28a

21.

Hiddemann W, Dreyling MH, Forstpointner R, et al. Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first-line therapy of follicular lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract 352]. Blood 2003; 102Suppl. 1: 104a

22.

Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgam-maRIIIa gene. Blood 2002; 99: 754–8PubMedCrossRef

23.

Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635–42PubMedCrossRef

24.

Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940–7PubMedCrossRef

25.

Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359–68PubMedCrossRef

26.

Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–42PubMedCrossRef

27.

Vose JM, Link BK, Grossbard ML, et al. Long term follow-up of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin’s lymphoma (NHL) [abstract 1396]. Blood 2002; 100Suppl. 1: 361a

28.

Habermann TM, Weiler EA, Morrisson VA, et al. Phase III trial of rituximab-CHOP (R-CHOP) vs CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma [abstract 8]. Blood 2003; 102Suppl. 1: 6a

29.

Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69: 584–91PubMed

30.

Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma: from clinical trials to clinical practice. J Nucl Med 2002; 43: 1507–29PubMed

31.

Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002; 20: 3545–57PubMedCrossRef

32.

Cheson BD. Radioimmunotherapy of non-Hodgkin’s lymphomas. Blood 2003; 101: 391–8PubMedCrossRef

33.

Wiseman GA, White CA, Witzig TE, et al. Radioimmunotherapy of relapsed non-Hodgkin’s lymphoma with Zevalin, a ⁹⁰Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 1999; 5Suppl. 10: 3281s–6sPubMed

34.

GlaxoSmithKline. Bexxar (tositumomab and iodine I ¹³¹ tositumomab) prescribing information. Research Triangle Park (NC), 2005 [online]. Available from URL: http://us.gsk.com/products/assets/us_bexxar.pdf [Accessed 2005 Aug 19]

35.

Zevalin (ibritumomab tiuxetan) prescribing information. In: Physicians’ desk reference. 59th ed. Montvale (NJ): Thomson PDR, 2005: 1738–43

36.

Zelenetz AD. Radioimmunotherapy for lymphoma. Curr Opin Oncol 1999; 11: 375–80PubMedCrossRef

37.

Juweid ME, Stadtmauer E, Hajjar G, et al. Pharmacokinetics, dosimetry, and initial therapeutic results with ¹³¹I- and (¹¹¹)In-/⁹⁰Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin’s lymphoma. Clin Cancer Res 1999; 5(10 Suppl.): 3292s–303sPubMed

38.

Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy with ⁹⁰Y ibritumomab tiuxetan (Zevalin). Semin Oncol 2003; 30(6 Suppl. 17): 6–10PubMedCrossRef

39.

Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. J Nucl Med 2003; 44: 465–74PubMed

40.

Wiseman GA, Pieslor PC, Gordon LI, et al. Increased stability and favorable pharmacokinetic profile associated with the second-generation tiuxetan chelator simplifies dosing methodology and obviates the need for determining whole body clearance for ⁹⁰yttrium-ibritumomab tiuxetan radiommunotherapy (RIT) of NHL [abstract]. 2003 Pan-Pacific Lymphoma Conference; 2003 Jul 21–26; Kohala Coast, Hawaii

41.

Wiseman GA, Leigh BR, Erwin WD, et al. Urinary clearance of ⁹⁰Y activity following Zevalin radioimmunotherapy of B-cell non-Hodgkin’s lymphoma [abstract 1124]. J Nucl Med 2001; 42(5 Suppl.): 268P

42.

Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999; 17: 3793–803PubMed

43.

Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term followup of a phase I/II study. Blood 2004; 103: 4429–31PubMedCrossRef

44.

Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin’s lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336–42PubMedCrossRef

45.

Schilder R, Molina A, Bartlett N, et al. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2004; 19: 478–81PubMed

46.

Murray JL, Witzig TE, Vo K, et al. Follow-up results of reduced dose ibritumomab tiuxetan (Zevalin) in thrombocytopenic patients with relapsed or refractory, low grade, follicular or CD20+ transformed B-cell non-Hodgkin’s lymphoma (L/F/T NHL) [abstract 1867]. Proc Am Soc Clin Oncol Meeting 2002; 21: 15b

47.

Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin lymphoma. J Clin Oncol 2002; 20: 3262–9PubMedCrossRef

48.

Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttri-um-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20: 2453–63PubMedCrossRef

49.

Gordon LI, Witzig T, Molina A, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004; 5: 98–101PubMedCrossRef

50.

Wiseman GA, Witzig TE, Murray JL, et al. Zevalin radioimmunotherapy (RIT) improves quality of life (QOL) in patients with low grade follicular, or transformed non-Hodgkin’s lymphoma (LG/F/T NHL) [abstract 3173]. Blood 2000; 96Suppl. 1: 734a

51.

Emmanouilides C, Murray JL, Vo K, et al. Earlier treatment with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkin’s lymphoma (NHL) [abstract 4949]. Blood 2003; 102Suppl. 1: 306b

52.

Witzig TE, Gordon L, Gaston I, et al. ⁹⁰Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy of follicular NHL: results by follicular subtype [abstract 1063]. Proc Am Soc Clin Oncol Meeting 2002; 21: 266a

53.

Morschhauser F, Huglo D, Martinelli G, et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial [abstract 130]. Blood 2004; 104Suppl. 1: 41a

54.

Bartlett NL, Witzig TE, Gordon L, et al. ⁹⁰Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin’s lymphoma (NHL) [abstract 51]. Proc Am Soc Clin Oncol Meeting 2002; 21: 14a

55.

Witzig TE, Emmanouilides C, Molina A, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy (RIT) induces durable complete responses (CR/CRu) in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) [abstract 2400]. Proc Am Soc Clin Oncol Meeting 2003; 22: 597

56.

Wiseman GA, Witzig TE. Yttrium-90 (⁹⁰Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Cancer Biother Radiopharm 2005; 20: 185–8PubMedCrossRef

57.

Czuczman MS, Emmanouilides CE, Witzig T, et al. Multivariate analysis of prognostic factors correlated with response to ⁹⁰Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin’s lymphoma [abstract 1062]. Proc Am Soc Clin Oncol Meeting 2002; 21: 266a

58.

Flinn IW, Witzig TE, White CA, et al. The Zevalin radioimmunotherapy (RIT) regimen is active in heavily pretreated, bulky, rituximab refractory NHL [abstract 1141]. Proc Am Soc Clin Oncol Meeting 2001; 20: 286a

59.

Emmanouilides C. Radioimmunotherapy for Waidenstrom’s macroglobulinemia. Semin Oncol 2003; 30: 258–61PubMedCrossRef

60.

Witzig TE, Gordon LI, Emmanouilides C, et al. Safety and efficacy of Zevalin in four patients with mucosa associated lymphoid tissue (MALT) lymphoma [abstract 4746]. Blood 2001; 98Suppl. 1: 254b

61.

O’Brien SM, Wierda W, Geisler D, et al. Yttrium-90 ibritumomab tiuxetan for minimal residual disease in CLL [abstract 2329]. Proc Am Soc Clin Oncol Meeting 2003; 22: 597

62.

Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphoma. J Clin Oncol 2003; 21: 1263–70PubMedCrossRef

63.

Emmanouilides CE, Witzig TE, Molina A, et al. Improved safety and efficacy of yttrium-90 ibritumomab tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade, follicular, and transformed B-cell non-Hodgkin’s lymphoma (NHL) [abstract 2392]. Proc Am Soc Clin Oncol Meeting 2003; 22: 595

64.

Wiseman GA, Gordon LI, Witzig TE, et al. Zevalin radioimmunotherapy is not associated with significant or prolonged depletion of T cells or natural killer cells [abstract 4817]. Blood 2000; 96Suppl. 1: 252b

65.

Gordon L, Witzig T, Schilder R, et al. High-dose therapy can be safely and successfully administered after Zevalin treatment [abstract 2681]. Proc Am Soc Clin Oncol Meeting 2001; 20: 232b

66.

Schilder RJ, Witzig LG, Emmanouilides CE, et al. ⁹⁰Y ibritumomab tiuxetan (zevalin) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma [abstract 1064]. Proc Am Soc Clin Oncol Meeting 2002; 21: 267a

67.

Ansell SM, Schilder RJ, Molina A, et al. Safety and efficacy of subsequent therapy in patients treated with yttrium-90-ibritumomab tiuxetan (^90Y-Zevalin) [abstract]. 2003 Pan-Pacific Lymphoma Conference; 2003 July 21–26; Kohala Coast, Hawaii

68.

Ansell SM, Schilder RJ, Pieslor PC, et al. Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin’s lymphoma: a review of the literature. Clin Lymphoma 2004; 5: 202–4PubMedCrossRef

69.

Wiseman GA, Colgan JP, Micallef INM, et al. Interim safety results of a phase I trial of two sequential doses of yttrium-90 ibritumomab tiuxetan for previously treated patients with low-grade non-Hodgkin’s lymphoma (NHL) [abstract 2312]. Proc Am Soc Clin Oncol Meeting 2003; 22: 575

70.

Ansell SM, Ristow KM, Habermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20: 3885–90PubMedCrossRef

71.

Fung HC, Forman SJ, Nademanee A, et al. A new preparative regimen for older patients with aggressive CD 20-positive B-cell lymphoma utilizing standard-dose yttrium-90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM followed by autologous hematopoietic cell transplantation (AHCT): targeted intensification without increased transplant-related toxicity [abstract 870]. Blood 2003; 102Suppl. 1: 248a

72.

Nademanee A, Forman SJ, Molina A, et al. High-dose radioimmunotherapy with yttrium 90 (⁹⁰Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin’s lymphoma (NHL): update of a phase I/II trial [abstract 6504]. Proc Am Soc Clin Oncol Meeting 2004; 23: 557

73.

Saleh F, Saleh M, Witzig T, et al. Rituximab administration subsequent to ibritumomab tiuxetan (Zevalin) radioimmunotherapy [abstract 30]. Proc Am Soc Clin Oncol Meeting 2002; 21: 8a

74.

Czuczman M, Witzig TE, Gaston I, et al. Zevalin radioimmunotherapy is not associated with an increased incidence of secondary myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) [abstract 1386]. Blood 2002; 100 Suppl. 1: 357a–58a

75.

Kantarjian HM, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 1987; 14: 435–43PubMed

76.

Pedersen-Bjergaard J, Ersboll J, Sorensen HM, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin’s lymphomas: comparison with results obtained in patients treated for Hodgkin disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 1985; 103: 195–200PubMed

77.

Pedersen-Bjergaard J, Andersen MK. Secondary or therapy-related MDS and AML and their chromosome aberrations: important to study but difficult to establish causality. Haematologica 1998; 83: 481–2PubMed

78.

Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. J Clin Oncol 2003; 21: 897–906PubMedCrossRef

79.

Kaminski MS, Tuck M, Estes J, et al. ¹³¹I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441–9PubMedCrossRef

80.

Armitage JO, Leonard JP, Gregory SA, et al. The effectiveness of tositumomab and iodine I¹³¹ tositumomab in relapsed/refractory follicular grade 1/2 and small lymphocytic non-Hodgkin’s lymphoma (NHL) [abstract 6573]. Proc Am Soc Clin Oncol Meeting. 2004; 22: 573

81.

Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288–94PubMedCrossRef

82.

Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose metho-trexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16: 3803–9PubMed

83.

Foran JM, Cunningham D, Coiffier B, et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 2000; 11Suppl. 1: 117–21PubMedCrossRef

84.

Ghielmini M, Schmitz SF, Burki K, et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma: Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000; 11Suppl. 1: 123–6PubMedCrossRef

85.

Romaguera J, Cabanillas F, Dang NH, et al. Mantle cell lymphoma (MCL): high rates of complete remission (CR) and prolonged failure-free survival (FFS) with Rituxan-HyperCVAD (R-HCVAD) without stem cell transplant (SCT) [abstract 3030]. Blood 2001; 98Suppl. 1: 726a

86.

Kahl BS, Bailey HH, Petroni G, et al. Phase II pilot study of modified hyper-CVAD plus rituximab for previously untreated mantle cell lymphoma: a Wisconsin Oncology Network study [abstract 4883]. Blood 2003; 102Suppl. 1: 290b

87.

Oki Y, Pro B, Delpassand E, et al. A phase II study of yttrium 90 (⁹⁰Y) ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract 2632]. Blood 2004; 104Suppl. 1: 720a

88.

Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–61PubMedCrossRef

89.

Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin’s Lymphoma. J Clin Oncol 1998; 16: 3257–63PubMed

90.

Vose JM, Bierman PJ, Lynch JC, et al. Phase I clinical trial of Zevalin (⁹⁰Y-ibritumomab) in patients with B-cell non-Hodgkin’s lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ACST) [abstract 92]. Blood 2003; 102Suppl. 1: 30a

91.

Davies AJ, Rohatiner AZS, Howell S, et al. Durable remissions and minor late toxicity may be obtained in patients treated at first or second recurrence of B cell non-Hodgkin’s lymphoma (NHL) with tositumomab and I¹³¹ tositumomab [abstract 2405]. Proc Am Soc Clin Oncol Meeting 2003; 22: 598

92.

Leonard JP, Coleman M, Kostakoglu L, et al. Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin’s lymphoma (NHL) [abstract 6518]. Proc Am Soc Clin Oncol Meeting 2004; 23: 560

93.

Link B, Kaminski MS, Coleman M, et al. Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin’s lymphoma (NHL) [abstract 6520]. Proc Am Soc Clin Oncol Meeting 2004; 23: 560

94.

Leonard JP, Coleman M, Kostakoglu L, et al. Fludarabine monophosphate followed by iodine-131 tositumomab for untreated low-grade and follicular NHL [abstract 393]. Blood 1999; 94Suppl. 1: 90a

95.

Sweetenham JW, Dicke K, Arcaroli J, et al. Efficacy and safety of yttrium 90 (⁹⁰Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma [abstract 2633]. Blood 2004; 104Suppl. 1: 720a

96.

Press OW, Unger JM, Braziel RM, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003; 102: 1606–12PubMedCrossRef

97.

National Cancer Institute. Phase III randomized study of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with either rituximab or iodine I¹³¹ tositumomab (monoclonal antibody anti-B1) in patients with newly diagnosed follicular non-Hodgkin’s lymphoma. Protocol ID: SWOG-S0016 [online]. Available from URL: http://www.cancer.gov/search/viewclinicaltrials.aspx?cdrid=68321&version=healthprofessional&protocolsearchid=1781966 [Accessed 2005 Aug 19]

98.

Shipley DL, Spigel DR, Carrell DL, et al. Phase II trial of rituximab and short duration chemotherapy followed by ⁹⁰Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: a Minnie Pearl Cancer Research Network phase II trial [abstract 6519]. Proc Am Soc Clin Oncol Meeting 2004; 23: 560

99.

Press OW, Leonard JP, Coiffier B, et al. Immunotherapy of non-Hodgkin’s lymphomas. Hematology (Am Soc Hematol Educ Program) 2001: 221-40

100.

Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin’s lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm 2000; 15: 15–29PubMedCrossRef

101.

Kaminski M, Estes J, Regan D, et al. Retreatment with Bexxar (tositumomab and iodine I-131 tositumomab) for patients with low-grade or transformed low-grade non-Hodgkin’s lymphoma (NHL) [abstract 1139]. Proc Am Soc Clin Oncol Meeting 2001; 20: 285a

102.

Witzig TE, Wiseman GA, Geyer SM, et al. A phase I trial of two-sequential doses of Zevalin radioimmunotherapy for relapsed low-grade B-cell non-Hodgkin’s lymphoma [abstract 1475]. Blood 2003; 102Suppl. 1: 406a

103.

Flinn IW, Kahl BS, Frey E, et al. Dose finding trial of yttrium 90 (⁹⁰Y) ib-ritumomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) [abstract 897]. Blood 2004; 104Suppl. 1: 256a

104.

Winter JN, Inwards DJ, Spies S, et al. ⁹⁰Y ibritumomab tiuxetan (Zevalin; 90YZ) doses higher than.4 mCi/kg may be safely combined with high-dose BEAM and autotransplant: the role for dosimetry [abstract 1162]. Blood 2004; 104Suppl. 1: 329a

105.

Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16: 3270–8PubMed

106.

Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934–42PubMed

107.

Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158–62PubMedCrossRef

108.

U.S. Food and Drug Administration. FDA Consumer Magazine; 2002 May-Jun [online]. Available from URL: http://www.fda.gov/fdac/departs/2002/302_upd.html [Accessed 2005 Aug 19]

109.

Grillo-López AJ. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients. Expert Rev Anticancer Ther 2002; 2: 323–9PubMedCrossRef

110.

National Cancer Institute. Comparative trial between Bexxar and Zevalin: protocol ID CCBX001-053 [online]. Available from URL: http://www.cancer.gov/search/viewclinicaltrials.aspx?cdrid=361581&version=healthprofessional&protocolsearchid=1782129 [Accessed 2005 Aug 19]

111.

Kaminski MS, Bennett J, Tuck M, et al. Lack of treatment-related MDS/AML in patients with follicular lymphoma after frontline therapy with tositumomab and iodine I 131 tositumomab [abstract 2313]. Proc Am Soc Clin Oncol Meeting 2003; 22: 575

112.

Chinn PC, Leonard JE, Rosenberg J, et al. Preclinical evaluation of ⁹⁰Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin’s lymphoma. Int J Oncol 1999; 15: 1017–25PubMed

113.

Wiseman G, Leigh B, Witzig T, et al. Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for cancer [abstract]. Eur J Nucl Med 2001; 28: 1198

114.

Cheson BD, Fisher RI. Monoclonal antibody therapy of hematologic malignancies: future directions. In: Cheson BD, editor. Monoclonal antibody therapy of h⨼atologic malignancies. Abington, England: Darwin Scientific Publications, 2001: 259–73

115.

Cheson BD. Some like it hot! J Clin Oncol 2001; 19: 3908–11PubMed

116.

Leonard JP, Kaminski MS, Coleman M. Iodine 131 labeled anti-B1 antibody (tositumomab) in the initial treatment of low-grade non-Hodgkin’s lymphoma. Cancer Invest 1999; 18Suppl. 1: 97–8

117.

Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the natural history of follicular lymphoma [abstract 583]. Blood 2004; 104Suppl. 1: 168a–69a

Titel: The Role of Radioimmunotherapy with Yttrium- 90 Ibritumomab Tiuxetan in the Treatment of Non-Hodgkin Lymphoma
verfasst von: Dr Bruce D. Cheson
Publikationsdatum: 01.09.2005
Verlag: Springer International Publishing
Erschienen in: BioDrugs / Ausgabe 5/2005
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI: https://doi.org/10.2165/00063030-200519050-00004

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2005

Anticalins in Drug Development

Toward Personalized Immunotherapy for Non-Hodgkin Lymphoma

Spotlight on Subcutaneous Recombinant Interferon-β-1a (Rebif®) in Relapsing-Remitting Multiple Sclerosis

Darbepoetin Alfa

Mechanisms of Action for Treatments in Multiple Sclerosis